Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?

Group 1 - Boston Scientific Corp (NYSE:BSX) is recognized as one of Goldman Sachs' top healthcare stocks, with TD Cowen stating that the stock's year-to-date decline seems excessive [1][3] - The company has shown a positive outlook for its pulsed-field ablation and Watchman products, with a reported revenue growth of 19.9% over the past 12 months, indicating strong operational momentum [3][4] - TD Cowen has reiterated a Buy rating on Boston Scientific with a price target of $100, following solid fourth-quarter and full-year 2025 earnings, where revenue rose 15.9% year over year and adjusted earnings per share reached $0.80, surpassing consensus estimates [4][5] Group 2 - Boston Scientific is a global leader in medical technology, specializing in the development, manufacturing, and marketing of less-invasive medical devices for various interventional specialties, including cardiology and urology [5]